Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | Addressing the imbalances & disparities amid COVID-19

Kenneth Anderson • 4 May 2020
COMy Virtual 2020
Multiple Myeloma Bortezomib BTK inhibitors Ibrutinib Selinexor

Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the ongoing COVID-19 pandemic and how it has impacted research and clinical practice. Additionally, Dr Anderson addresses research that is being applied from multiple myeloma into COVID-19. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kenneth Anderson

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Defining high-risk multiple myeloma: recent advances in the field & future considerations
Francesco Maura et al. • 4 Nov 2024
Collaboration in the myeloma community 1:27
Collaboration in the myeloma community
Kenneth Anderson • 14 May 2022
The future of myeloma treatment and the possibility of cure 4:04
The future of myeloma treatment and the possibility of cure
Kenneth Anderson • 14 May 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals